CA-125 monitored therapy with GnRH analogue of pelvic endometriosis.

P Negri, Pedro Negri, Melissa Ricciardelli, M A Ricciardelli, A Tomasi, Elisa Grechi, E Grechi, R M Fortini
Acta Europaea fertilitatis · 1994 · vol. 23(4) , pp. 171–4 · PMID:1343472 · W2413799565
article OA: closed CC0
View on OpenAlex View on PubMed

Abstract

Thirteen patients affected by endometriosis have been treated with GnRH analogue Buserelin. CA-125 serum levels have been monitored before, during and after treatment. Analysis of data suggests the hypothesis of an individualized follow up by means of repeated assays of CA-125 and their reference to pre and post treatment graphs.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Antigens, Tumor-Associated, Carbohydrate Buserelin Endometriosis Pelvic Neoplasms Adult Analysis of Variance Antigens, Tumor-Associated, Carbohydrate Buserelin Buserelin Endometriosis Endometriosis Endometriosis Estradiol Estradiol Female Follicle Stimulating Hormone Follicle Stimulating Hormone Follow-Up Studies Humans Luteinizing Hormone

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

europepmc
last seen: 2026-06-29T06:08:12.325296+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:11:49.821429+00:00
License: CC0 · commercial use OK